Skip to content

A multicenter real-world clinical study evaluating the safety of Lipitor capsules

A multicenter real-world clinical study evaluating the safety of Lipitor capsules

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083958
Enrollment
Unknown
Registered
2024-05-08
Start date
2024-05-10
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

Lipitor capsule standard dose group:Oral, 3 capsules at a time, 2 times a day, morning and evening after meals or according to the doctor's advice, it is recommended to use for 3 to 6 months

Sponsors

wenzhou peoples hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patients with clinical application of lipitor capsules; 2. Obtain informed consent and signature from the patient

Exclusion criteria

Exclusion criteria: 1. There are any contraindications or other circumstances that prohibit the use of Lipitor capsules according to the contraindications and precautions listed in the instructions approved by Lipitor capsules; 2, poor compliance, unable to complete or refuse to complete the interviewer; 3. Patients with mental disorders and other factors affecting compliance; 4. Allergic to the components of this medicine; 5. Researchers believe that candidates are not suitable for admission

Design outcomes

Primary

MeasureTime frame
Blood routine examination;Blood lipid;

Secondary

MeasureTime frame
Adverse event;

Countries

China

Contacts

Public ContactXiaoshu Chen

Wenzhou People's Hospital

40707729@qq.com+86 135 0666 2820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026